Drug market has changed

July 2009
Slovak Spectator;7/20/2009, Vol. 15 Issue 28, p3
No abstract available.


Related Articles

  • FDA Halts Parking Lot Campouts. Sellers, L.J. // Pharmaceutical Executive;Sep2003, Vol. 23 Issue 9, p18 

    Reports on the changes in the pharmaceutical industry market in the U.S. Cost of generic drugs; Safety of drugs; Competition in the drugs market.

  • Genentech awards cancer drug to C&W. Herskovits, Beth // Medical Marketing & Media;May2005, Vol. 40 Issue 5, p30 

    Reports that Genentech Inc. has awarded Cohn & Wolfe the advertising account for its anticancer drug, Rituxan, which had belonged to Ketchum Advertising. Reasons for the change; Genentech's co-marketing of the drug with Biogen Idec.

  • New reimbursement schemes for Russia, Ukraine and Kazakhstan.  // PharmacoEconomics & Outcomes News;5/25/2013, Issue 679, p10 

    The article reports that the research and consulting company PMR has asserted that the plan of Russia, Ukraine and Kazakhstan to introduce drug reimbursement modes could change the operating environment on both the generic and innovative drug markets in these countries.

  • Critical Therapeutics seeks asthma drug OK.  // PharmaWatch: Biotechnology;May 2005, Vol. 4 Issue 5, p10 

    Reports that Massachusetts-based biopharmaceutical firm, Critical Therapeutics (CT) has submitted a supplemental new drug application to the United States Food and Drug Administration for the investigational asthma drug, Zyflo Filmtab. Application of CT to allow the company to begin marketing...

  • Reforms on drug safety.  // Nature;9/28/2006, Vol. 443 Issue 7110, p372 

    The author reflects on the changes on drug safety in the U.S. According to the Institute of Medicine, the Food and Drug Administration (FDA) has neither the fund nor the brawn to maintain the safety of drugs. Several assessments has confirmed that the post-market safety efforts of the FDA were...

  • ANOTHER FINE MESS. Jack, Andrew // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;7/28/2012, Vol. 345 Issue 7867, p20 

    The article discusses illegal promotion strategies used by pharmaceutical companies to market drugs to doctors. A settlement reached earlier this year requires drug giant GlaxoSmithKline (GSK) to pay a fine of 3 billion dollars for illegal drug promotion. Drug companies are now taking steps to...

  • New Multiple Sclerosis Drugs Could Offer Breakthroughs. AMY REEVES // Investors Business Daily;9/29/2014, pA06 

    Over the last four years, life for multiple-sclerosis patients has changed for the better as a new generation of powerful oral drugs has moved into a market dominated by injectables.

  • Liability for dispensing a drug withdrawn from the market. Brushwood, David B. // Pharmacy Today;Nov2008, Vol. 14 Issue 11, p57 

    The article announces that the Supreme Court of Utah has added another exception to the general no duty to warn rule. Accordingly, this exception applies when a pharmacist is alleged to have dispensed a prescribed drug after the drug has been withdrawn from the market by the Food and Drug...

  • LINKED TV SPOTS WITHOUT RISK MAY BE OK. Dickinson, James G. // Medical Marketing & Media;Sep2001, Vol. 36 Issue 9, p38 

    Reports on changes in the drug advertising policy implemented by the Division of Drug Marketing, Advertising, and Communications of the Food and Drug Administration in the U.S.

  • FDA unveils plans to deal with boom of regulated imports. Pecquet, Julian // Hill;6/21/2011, Vol. 18 Issue 89, p22 

    The article reports that the U.S. Food and Drug Administration (FDA) has called for a dramatic change in strategy due to the explosion of products, manufacturers and countries involved in FDA-regulated markets.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics